Patients with diabetes are susceptible to dementia, but regular therapy fails to reduce the risk of dementia. In previous observational study, the investigators found that liraglutide can improve cognitive function in patients with T2DM through a metabolism-independent pathway. Here the investigators aim to further verify such effects through a randomized, controlled study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
30
Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. We had fond its cognitive improvement effects in an observational study. In order to confirm the effects, the investigators conduct a randomized, controlled study.
oral antidiabetic drugs (OADs) or insulin, except for glucagon-like peptide type 1 (GLP-1) analogues
The third hospital affiliated to the Third Military Medical University
Chongqing, Chongqing Municipality, China
Changes in cognitive function from baseline to 12 weeks
MMSE
Time frame: 0 week, 12 week
Changes of metabolic parameters from baseline to 12 weeks
Systolic and diastolic blood pressure
Time frame: 0 week, 12 week
Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks
Aβ42
Time frame: 0 week, 12 week
Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks
tau
Time frame: 0 week, 12 week
Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks
P-tau
Time frame: 0 week, 12 week
Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks
TDP-43
Time frame: 0 week, 12 week
Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks
IL-6
Time frame: 0 week, 12 week
Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks
IL-8
Time frame: 0 week, 12 week
Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
TNF-a
Time frame: 0 week, 12 week
Changes of metabolic parameters from baseline to 12 weeks
HbA1c
Time frame: 0 week, 12 week
Changes of metabolic parameters from baseline to 12 weeks
fasting plasma glucose
Time frame: 0 week, 12 week
Changes of metabolic parameters from baseline to 12 weeks
body mass index
Time frame: 0 week, 12 week
Changes of metabolic parameters from baseline to 12 weeks
lipid profile
Time frame: 0 week, 12 week
Changes of metabolic parameters from baseline to 12 weeks
waist circumference
Time frame: 0 week, 12 week